Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Clinical & Medical Microbiology Volume 1 (2016), Article ID 1:IJCMM-103, 5 pages
https://doi.org/10.15344/2456-4028/2016/103
Research Article
The Role of Tigecycline in the Era with Multi-drug Resistant Organisms (MDROs) the Experience of a Medical Center in Taiwan

Mei-Chun Lee1,3, Chien-Hung Lu1, Wei-Ying Lee1 and Chun-Ming Lee2,3,4,5*

1Department of Pharmacy, MacKay Memorial Hospital, Taipei, Taiwan
2Division of Infectious Disease, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan
3Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan
4MacKay Medical College, New Taipei City, Taiwan
5Department of Internal Medicine, St. Joseph’s Hospital, Yunlin County, Taiwan
Chun-Ming Lee, 74, Sinsheng Rd., Huwei Township, Yunlin County, Taiwan, Tel: +886-5-6337333 Fax: +886-5-6325079; E-mail: leecm4014@yahoo.com.tw
23 January 2016; 28 February 2016; 03 March 2016
Lee MC, Lu CH, Lee WY, Lee CM (2016) The Role of Tigecycline in the Era with Multi-drug Resistant Organisms (MDROs) the Experience of a Medical Center in Taiwan. Int J Clin Med Microbiol 1: 103. doi: https://doi.org/10.15344/2456-4028/2016/103
© 2016 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee (2007) Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 35: S165-S193 [CrossRef] [Google Scholar] [PubMed]
  2. Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY (2011) Emergency and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect 44: 157-165 [CrossRef] [Google Scholar] [PubMed]
  3. Tseng SH, Lee CM, Lin TY, Chang SC, Chuang YC, et al. (2012) Combating antimicrobial resistance: Antimicrobial stewardship program in Taiwan. J Microbiol Immunol Infect 45: 79-89 [CrossRef] [Google Scholar] [PubMed]
  4. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, et al. (2005) The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41: S354-S367 [CrossRef] [Google Scholar] [PubMed]
  5. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5: S341-353 [CrossRef] [Google Scholar] [PubMed]
  6. Tanaseanu C, Milutinovic S, Calistru PI, Strausz J, Zolubas M, et al. (2009) Efficacy and safety of tigecycline versus levofloxacin for communityacquired pneumonia. BMC Pulm Med 9: 44 [CrossRef] [Google Scholar] [PubMed]
  7. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, et al. (2010) Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 10: 287 [CrossRef] [Google Scholar] [PubMed]
  8. Eckmann C, Heizmann WR, Leitner E, Eiff CC, Bodmann FF (2011) Prospective, non-interventional, multi-center trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 57: 275-284 [CrossRef] [Google Scholar] [PubMed]
  9. Renteria M, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, et al. (2014) In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012. Diagn Microbiol Infect Dis 79: 54-59 [CrossRef] [Google Scholar] [PubMed]
  10. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, et al. (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68: 140-151 [CrossRef] [Google Scholar] [PubMed]
  11. Kuo SC, Wang FD, Fung CP, Chen LY, Chen SJ, et al. (2011) Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 44: 45-51 [CrossRef] [Google Scholar] [PubMed]
  12. John G, Paul GA, Paul A (2011) Johns Hopkins ABX Guide: Diagnosis and Treatment of Infectious Diseases. (3rd edition), Jones & Bartlett Learning press, Burlington, MA, USA, 605p
  13. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM (2007) Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27: 1198-1201 [CrossRef] [Google Scholar] [PubMed]
  14. Gerald KM, Elaine KS, Jane M, Linda K, Joan DH, Sarah ED (2012) AHFS Drug Information. Amer Soc of Health System press, Bethesda, Maryland, USA, pp. 452-453
  15. Cada DJ, Levien T, Baker DE (2005) Tigecycline. Hospital Pharmacy 40: 897-907
  16. Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2005
  17. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, et al. (2010) Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Disease Society of America. Clin Infect Dis 50: 133-64 [CrossRef] [Google Scholar] [PubMed]
  18. Martín-Gandul C, García-Cabrera E, Castillo-Ojeda E, Jiménez-Mejías ME (2012) More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. J Antimicrob Chemother 67: 1048-1049 [CrossRef] [Google Scholar] [PubMed]
  19. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, et al. (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46: 567-570 [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2023 Graphy Publications, All Rights Reserved.